Drug class
Alkalinising agent; urinary citrate source and calcium-complexing ligand
Mechanism of action
Citrate is metabolised to bicarbonate, increasing systemic and urinary alkalinity. In urine it complexes calcium and increases urinary citrate, reducing supersaturation of calcium salts and inhibiting stone crystallisation. Sodium or potassium counter-ions affect electrolyte load and patient selection, but do not create a different citrate pharmacological target.
General use cases
- Prevention and treatment of recurrent calcium-containing kidney stones associated with hypocitraturia
- Alkali replacement in selected patients with renal tubular acidosis and hypocitraturia
- Urinary alkalinisation in selected uric-acid or cystine stone disorders, depending on the specific citrate formulation and local product information
Citrate provides the alkalinising/complexing moiety. Potassium is a pharmacologically relevant electrolyte and changes safety considerations (e.g. hyperkalaemia), not the core citrate target.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
